In our sample, a total of 254,523 patients had T2DM. The prevalence of T2DM was 4.69 % (women: 3.26%; men: 6.03%). The average age of these T2DM patients was 64.8 years, and 66.4% were male. The incidence of T2DM in our sample was 4.889 cases per 1,000 personyears in men and 2.863 cases in 1,000 person-years in women. T2DM prevalence/ incidence strongly depended on gender and age. Whereas the T2DM prevalence in both men and women was below 0.9% in all age groups Ͻ40 years, it increased up to 25.17% (men)/24.34% (women) in the second-highest age group, 85-90 years. CONCLUSIONS: A comparison of the distribution of AF prevalence/incidence in our population with that in already published studies shows that our figures are comparatively high. Obviously, in a large industrial nation such as Germany, care provision structures are going to be challenged by the requirement to treat more T2DM patients in the future. 
PDB26 FACTORS ASSOCIATED WITH THREE YEARS OF GOOD OR POOR HEMOGLOBIN A1C CONTROL AMONG PATIENTS WITH DIABETES
Juarez
OBJECTIVES:
To determine which factors were associated with sustained poor or good glycemic control over three years. METHODS: This retrospective study of enrollees in a large health plan in Hawaii with diabetes was restricted to those with poor control at baseline (HbA1cϾ9% in the year 2006), who had HbA1c values for four years (2006-2009, nϭ2970 . Longer diabetes duration and higher morbidity increased the risk of poor control, while patients taking 15ϩ medications decreased the risk. CONCLUSIONS: As diabetes duration strongly predicted poor control, primary prevention to decrease early onset of diabetes might be a cost-effective means to reduce the number of patients with poor control. Our findings that younger patients with diabetes are most likely to have poor control suggest that interventions need to be targeted to this population.
DIABETES/ENDOCRINE DISORDERS -Cost Studies

PDB28 SPENDING ON MEDICINES AND INPUTS TO CONTROL DIABETES IN THE STATE OF MINAS GERAIS. BRAZIL
Souza KM, Figueiredo ACDD, Villela E, Garcia M, Pereira V, Silva L, Souza AL Health Secretary of Minas Gerais, Brazil, Belo Horizonte, Minas Gerais, Brazil OBJECTIVES: Diabetes mellitus is a syndrome characterized by chronic hyperglycemia with absolute or relative deficiencies of insulin and/or in its action. The National Health System (SUS), through the pharmaceutical assistance must ensure medications and supplies needed for the monitoring of capillary blood glucose of diabetic patients, defined by ministerial decree. The aim of this study is to evaluate the financial impact of inputs for monitoring capillary blood glucose in relation to medicinal products for treatment of diabetes mellitus in the state of Minas Gerais in 2011. METHODS: Survey distribution and financial cost through the computerized management of pharmaceutical assistance (SIGAF) in thez State of Minas Gerais in 2011 of oral antidiabetics (glibenclamide 5 mg and metformin hydrochloride 850mg), human insulin NPH and regular human insulin and indicator strip that measures the glucose. RESULTS: The costs for regular and NPH Insulin in 2011 were U$8.320.793,31, with oral antidiabetic agents was U$2.032.284,77, as with reagent strips for monitoring blood glucose level was U$6.978.321,99.The total spending on drugs for the treatment of diabetes mellitus was U$10.353.078,08. It is observed that the cost of test strips correspond to approximately 67.5% of this value. CONCLUSIONS: These results demonstrate that the costs of inputs for monitoring of blood glucose have a significant financial impact on the State diabetes program. Moreover, they suggest the need for research regarding the reasonableness of the use of these inputs by patients. Education strategies, such as the pharmaceutical guidance for patients who perform self-monitoring blood glucose levels, aid in the proper use of these inputs and can avoid any waste. 
PDB29 BUDGET IMPACT ANALYSIS OF NORDITROPIN VERSUS THREE LEADING MARKET GROWTH HORMONE THERAPIES
OBJECTIVES:
To assess the cost of various market share scenarios of leading recombinant human growth hormone (rhGH) pens to a commercial health plan, taking into consideration drug and wastage costs due to device design. METHODS: A budget impact model (BIM) was developed to determine the costs of rhGH products. Key model inputs included plan size, number of pediatric and adult patients, mean [SD] weight, product dosing increments and annual wastage due to pen devices having varying dosing increments. The BIM included storage and reconstitution wastage as an option. Pediatric (nϭ900) and adult (nϭ100) patient weights were assumed to be normally distributed with mean (SD) 30.25 (4.00) and 75.00 (2.00) kg. Assumed base case dosages were 0.03 mg/kg daily for pediatric patients; brand-specific based on product package inserts for adult patients. Market share was indexed at Year 1 (2011) and presented with 10%, 15% and 20% shifts to Norditropin from Genotropin, Humatrope, and Nutropin. Costs were based on WAC in US dollars. RESULTS: Costs per patient per year (PPPY) were higher for Genotropin, Humatrope and Nutropin vs. Norditropin ranging from approximately $23.1K to $24.6K in pediatrics and $8.1 K to $9.2K in adults. Norditropin was associated with the lowest annual milligrams of wastage (9.1 mg pediatric/ 8.5 mg adult, including wastage due to storage and reconstitution) across all pen dosages, followed by Nutropin (20.7 mg/ 19.9 mg), Humatrope (20.7 mg/20.2 mg) and Genotropin (30.6 mg/ 30.3 mg). Norditropin remained the least costly per year when: dosing from package inserts was used, adult dosing was fixed, and when storage and reconstitution wastage was not included. CONCLUSIONS: Due to differences in cost per mg and wastage associated with design among the leading GH brands on the market, use of Norditropin pens may result in cost savings. 
PDB30 A COMPARISON OF THE COSTS FOR TREATING CENTRAL PRECOCIOUS PUBERTY DURING THE FIRST YEAR WITH LEUPROLIDE ACETATE INJECTIBLE AND HISTRELIN ACETATE IMPLANT
OBJECTIVES:
Central precocious puberty (CPP) is generally treated with gonadotropin releasing hormone (GnRH) agonists. The objective was to compare the costs of first year treatment of monthly leuprolide acetate injections and once-a-year histrelin acetate implants. METHODS: Two retrospective cohort studies were conducted using datasets derived from the Thomas Reuter's MarketScan© Multi-State Medicaid Database (2003 -2007 and the MarketScan© Commercial Database (2005 -2009 . Inclusion criteria were 2 claims with target diagnoses occurring 30 or more days apart, enrollment for 3ϩ months before first treatment, and continuous enrollment for 12ϩ months after first treatment. A probabilistic patient flow model was developed using estimates for treatment patterns and costs for products, office visits, and monitoring therapy. RESULTS: A total of 4802 Medicaid and 7391 Commercial beneficiaries age 12 years or younger were identified as diagnosed with CPP. 323 Medicaid and 383 Commercial beneficiaries met the inclusion criteria and were treated with leuprolide for 365 days or more. Medicaid and Commercial patients compliant with leuprolide (13ϩ treatments/year) had an average of 14.8 and 14.0 treatments, respectively. Fifty-three percent of Medicaid and 54% of Commercial patients were non-compliant and averaged 9.2 and 7.7 treatments, respectively. Cost for treating 100 patients were simulated using existing levels of noncompliance and an assumption that all patients should be compliant. Based on current levels of non-compliance, costs for histrelin implants were 1.9% lower in Medicaid and 6.5% higher in Commercial plans-however, when based on full compliance, costs for histrelin implants were 12.9% lower in Medicaid and 12.1% lower in Commercial plans. CONCLUSIONS: With current levels of non-compliance with GnRH agonists, costs for CPP treatment is similar in Medicaid and slightly less A175 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
